Intellia Therapeutics (NTLA) Return on Sales (2016 - 2025)
Intellia Therapeutics (NTLA) has disclosed Return on Sales for 11 consecutive years, with 4.01% as the latest value for Q4 2025.
- On a quarterly basis, Return on Sales rose 577.0% to 4.01% in Q4 2025 year-over-year; TTM through Dec 2025 was 6.09%, a 232.0% increase, with the full-year FY2025 number at 6.09%, up 232.0% from a year prior.
- Return on Sales was 4.01% for Q4 2025 at Intellia Therapeutics, up from 7.6% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 66.48% in Q4 2023 to a low of 238.81% in Q3 2021.
- A 5-year average of 16.48% and a median of 7.76% in 2022 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: plummeted -23756bps in 2021, then soared 23101bps in 2022.
- Intellia Therapeutics' Return on Sales stood at 6.22% in 2021, then fell by -24bps to 7.72% in 2022, then soared by 961bps to 66.48% in 2023, then crashed by -115bps to 9.77% in 2024, then soared by 59bps to 4.01% in 2025.
- Per Business Quant, the three most recent readings for NTLA's Return on Sales are 4.01% (Q4 2025), 7.6% (Q3 2025), and 7.2% (Q2 2025).